Benefits of Early Aspirin Discontinuation in Low-Risk Heart Attack Patients
Research shows that early discontinuation of aspirin after MI in low-risk patients can reduce bleeding risk without increasing adverse events, thanks to advancements in revascularization techniques.
Recent research suggests that for low-risk patients who experience a myocardial infarction (heart attack) and undergo early complete revascularization, stopping aspirin therapy after one month may be safe and beneficial. A large European trial involving nearly 2,000 participants demonstrated that switching from dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy after one month did not increase the risk of adverse cardiovascular events such as death, heart attacks, or stroke. Instead, this approach significantly reduced bleeding complications, a common concern with prolonged aspirin use.
The study, presented at ESC Congress 2025 and published in the New England Journal of Medicine, involved patients who received modern drug-eluting stents and achieved complete revascularization within a week of their MI. These participants continued with DAPT—aspirin plus a P2Y12 inhibitor—for one month, after which they were randomized to either remain on DAPT or switch to P2Y12 inhibitor monotherapy for the following 11 months.
Findings showed comparable rates of major cardiovascular events between both groups, with the monotherapy group experiencing fewer significant bleedings. The overall composite outcome—covering death, MI, stent thrombosis, stroke, and major bleeding—was lower in patients who discontinued aspirin early. Lead investigator Professor Giuseppe Tarantini explained that in carefully selected low-risk patients, early de-escalation could balance protection from ischemic events while minimizing bleeding risks, thanks to advancements in stent technology and medical care.
These results challenge traditional guidelines, which recommend 12 months of DAPT after MI, suggesting that tailored, shorter-duration therapy may be appropriate for certain low-risk groups. The study highlights the importance of modern revascularization techniques and personalized therapy in optimizing patient outcomes.
Source: https://medicalxpress.com/news/2025-09-early-aspirin-discontinuation-linked-benefits.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Targeting Mitochondrial Protein VDAC2 Could Enhance Liver Cancer Treatments
Researchers have identified VDAC2, a mitochondrial protein, as a promising target to enhance selective liver cancer treatments, potentially improving patient outcomes with targeted therapy.
The Impact of Hospital and Insurer Disputes on Patient Care
Recent disputes between hospitals and insurers are leading to delays and confusion for patients seeking vital care. Rising costs and hospital mergers are fueling more disagreements, putting patient access at risk. Learn how you can navigate these challenges.
Advanced Machine Learning Enhances 3D Imaging for Fetal Health Assessment
Innovative machine learning techniques are now enabling detailed 3D modeling of fetal health, improving measurement accuracy and diagnostics through advanced MRI analysis.
Sierra Leone Reports Over 2,000 Mpox Cases and 11 Deaths Amid Rising Outbreak
Sierra Leone reports over 2,000 mpox cases and 11 deaths this year amid rising infection rates, prompting urgent vaccination efforts and healthcare response.